TY - JOUR
T1 - High serum ferritin levels in newly diagnosed patients with myelodysplastic syndromes are associated with greater symptom severity
AU - Caocci, Giovanni
AU - Vignetti, Marco
AU - Patriarca, Andrea
AU - Breccia, Massimo
AU - Platzbecker, Uwe
AU - Palumbo, Giuseppe A.
AU - Stauder, Reinhard
AU - Cottone, Francesco
AU - Petranovic, Duska
AU - Voso, Maria Teresa
AU - Tafuri, Agostino
AU - Invernizzi, Rosangela
AU - Caers, Jo
AU - Luppi, Mario
AU - La Nasa, Giorgio
AU - Niscola, Pasquale
AU - Efficace, Fabio
PY - 2020/1/1
Y1 - 2020/1/1
N2 - We examined the association between serum ferritin (SF) levels and patient-reported functional aspects and symptoms, as measured by the EORTC QLQ-C30, in newly diagnosed patients with myelodysplastic syndromes (MDS). Analysis was conducted on 497 MDS patients who were classified in two groups based on the SF value of 1000 ng/mL. Clinically relevant differences of patient-reported functional and symptom scales were evaluated and classified as small, medium and large, based on established thresholds. Multivariable linear regression analysis was performed to account for potential confounding factors. Patients with SF of ≥ 1000 ng/mL reported statistically significant and clinically relevant worse outcomes across various health domains. Dyspnea was the symptom indicating the largest difference and mean scores of patients with higher and lower SF levels were 40 and 24.3, respectively (p = 0.005), indicating a large clinically relevant difference (Δ = 15.7). Further research is needed to better understand the relationship between SF levels and specific health-related quality of life domains.
AB - We examined the association between serum ferritin (SF) levels and patient-reported functional aspects and symptoms, as measured by the EORTC QLQ-C30, in newly diagnosed patients with myelodysplastic syndromes (MDS). Analysis was conducted on 497 MDS patients who were classified in two groups based on the SF value of 1000 ng/mL. Clinically relevant differences of patient-reported functional and symptom scales were evaluated and classified as small, medium and large, based on established thresholds. Multivariable linear regression analysis was performed to account for potential confounding factors. Patients with SF of ≥ 1000 ng/mL reported statistically significant and clinically relevant worse outcomes across various health domains. Dyspnea was the symptom indicating the largest difference and mean scores of patients with higher and lower SF levels were 40 and 24.3, respectively (p = 0.005), indicating a large clinically relevant difference (Δ = 15.7). Further research is needed to better understand the relationship between SF levels and specific health-related quality of life domains.
KW - Functional status
KW - Myelodysplastic syndromes
KW - Quality of life
KW - Serum ferritin
KW - Symptoms
KW - Transfusions
UR - http://www.scopus.com/inward/record.url?scp=85086837542&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85086837542&partnerID=8YFLogxK
U2 - 10.1007/s12185-020-02920-y
DO - 10.1007/s12185-020-02920-y
M3 - Article
C2 - 32588394
AN - SCOPUS:85086837542
JO - International Journal of Hematology
JF - International Journal of Hematology
SN - 0925-5710
ER -